How to Engineer a Biotech Exit Before You Raise a Dime
The best biotech exits are built at seed, not sold at the end. A step-by-step playbook for lining up your acquirer years before the deal.
Lavine Hemlani
Founder & CEO
The best biotech exits are engineered before the company raises a single dollar. A $300M+ acquisition I heard about recently was built exactly this way: the founder put the eventual acquirer in the room on day one. Pharma venture teams sat in on the seed calls — not to invest, but to validate the science. When the data read out, the buyer was already convinced, and the deal closed at a price a cold process could never have reached.
Most founders do the opposite. They build in a cave for five years, then go hunting for a buyer with a cold deck. That's backwards. Here is the version that actually works.
1. Name your six buyers now
In any indication, the realistic acquirers are a short list — often no more than six names. You know who they are at seed, not at Series B. Write them down before you raise a dollar. Everything else in this playbook flows from that list.
2. Go in through their venture arm, not their M&A team
Almost every large pharma runs a venture arm — Lilly Ventures, Pfizer Ventures, Bristol Myers Squibb, Novartis, and others. A small check or even an advisory seat from one of them isn't really about the money. It's a signal that travels inside the company to the exact people who eventually sign acquisitions. The M&A team is where you go to sell; the venture arm is where you go to be discovered.
3. Ask the question founders are afraid to ask
Ask each of them directly: "What would you need to see to believe this?" Their scientists will tell you the precise data that would de-risk the asset in their eyes. That answer becomes your trial design. You stop guessing what de-risks your program and start building exactly what the buyer already told you they need.
4. Report to all six like they're already investors
Send quarterly updates. Make sure every milestone lands in their inbox. By the time you have a readout, you are not a cold pitch — you are a company they have watched de-risk for two years. Familiarity plus data is what turns a maybe into a term sheet.
Why this works
An acquisition is a decision made under uncertainty. Everything above removes uncertainty ahead of time: the buyer helped define the data, watched you hit it, and already trusts the team. You are not pitching an exit at the end — you are delivering one they already asked for.
The corollary is that your financials and diligence materials have to be ready long before you think you need them. Buyers who have followed you for two years will move fast when the data lands, and a messy data room is the one thing that can stall a deal that was otherwise won years earlier.
Frequently asked questions
When should a biotech start building acquirer relationships?
At seed, before you raise. The realistic acquirers in your indication are knowable on day one, and the earlier they see the science, the more your eventual data means to them.
Should I approach a pharma's M&A team or its venture arm?
The venture arm. A small investment or advisory relationship signals internally to the people who sign acquisitions, without the adversarial framing of an M&A conversation.
How do I know what data an acquirer wants?
Ask them: "What would you need to see to believe this?" Their scientists will name the specific readouts. Build your trial design around that answer.
Zenith helps life sciences founders get transaction-ready — clean financials, a defensible data room, and a fundraising narrative built for the buyers who matter. Book a Transaction Readiness Audit.
Need help with your financials?
Let's build your financial foundation together.